Literature DB >> 18594778

Genetic evidence of PEBP2beta-independent activation of Runx1 in the murine embryo.

Tomomasa Yokomizo1, Masatoshi Yanagida2, Gang Huang3, Motomi Osato4,5, Chikako Honda1, Masatsugu Ema1, Satoru Takahashi1, Masayuki Yamamoto1,6, Yoshiaki Ito2,7.   

Abstract

The Runx1/AML1 transcription factor is required for the generation of hematopoietic stem cells and is one of the most frequently targeted genes in human leukemia. Runx1-deficient mice die around embryonic day (E)12.5 due to severe hemorrhage in the central nervous system and the complete absence of definitive hematopoietic cells. Since mice lacking the heterodimeric partner of Runx1, PEBP2beta/CBFbeta, are almost identical in phenotype to Runx1 (-/-) mice, PEBP2beta was believed to be essential for the in vivo function of Runx1. Here we show that transgenic overexpression of Runx1 partially rescues the lethal phenotype of PEBP2beta-deficient mice at E12.5. Some of the rescued mice escaped from the severe hemorrhage at E11.5-12.5, although definitive hematopoiesis was not restored. Thus, PEBP2beta-independent Runx1 activation can occur in vivo. This observation sheds new light on the mechanism(s) that regulate the activity of Runx transcription factors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18594778     DOI: 10.1007/s12185-008-0121-4

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  27 in total

1.  Biophysical characterization of interactions between the core binding factor alpha and beta subunits and DNA.

Authors:  Y Y Tang; B E Crute; J J Kelley; X Huang; J Yan; J Shi; K L Hartman; T M Laue; N A Speck; J H Bushweller
Journal:  FEBS Lett       Date:  2000-03-24       Impact factor: 4.124

Review 2.  Core-binding factors in haematopoiesis and leukaemia.

Authors:  Nancy A Speck; D Gary Gilliland
Journal:  Nat Rev Cancer       Date:  2002-07       Impact factor: 60.716

3.  Absence of fetal liver hematopoiesis in mice deficient in transcriptional coactivator core binding factor beta.

Authors:  K Sasaki; H Yagi; R T Bronson; K Tominaga; T Matsunashi; K Deguchi; Y Tani; T Kishimoto; T Komori
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-29       Impact factor: 11.205

4.  The erythroid phenotype of EKLF-null mice: defects in hemoglobin metabolism and membrane stability.

Authors:  Roy Drissen; Marieke von Lindern; Andrea Kolbus; Siska Driegen; Peter Steinlein; Hartmut Beug; Frank Grosveld; Sjaak Philipsen
Journal:  Mol Cell Biol       Date:  2005-06       Impact factor: 4.272

5.  Hematopoiesis in the fetal liver is impaired by targeted mutagenesis of a gene encoding a non-DNA binding subunit of the transcription factor, polyomavirus enhancer binding protein 2/core binding factor.

Authors:  M Niki; H Okada; H Takano; J Kuno; K Tani; H Hibino; S Asano; Y Ito; M Satake; T Noda
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-27       Impact factor: 11.205

6.  Characterization of GATA-1(+) hemangioblastic cells in the mouse embryo.

Authors:  Tomomasa Yokomizo; Satoru Takahashi; Naomi Mochizuki; Takashi Kuroha; Masatsugu Ema; Asami Wakamatsu; Ritsuko Shimizu; Osamu Ohneda; Motomi Osato; Hitoshi Okada; Toshihisa Komori; Minetaro Ogawa; Shin-Ichi Nishikawa; Yoshiaki Ito; Masayuki Yamamoto
Journal:  EMBO J       Date:  2006-12-07       Impact factor: 11.598

7.  Requirement of Runx1/AML1/PEBP2alphaB for the generation of haematopoietic cells from endothelial cells.

Authors:  T Yokomizo; M Ogawa; M Osato; T Kanno; H Yoshida; T Fujimoto; S Fraser; S Nishikawa; H Okada; M Satake; T Noda; S Nishikawa; Y Ito
Journal:  Genes Cells       Date:  2001-01       Impact factor: 1.891

8.  Runx1 is essential for hematopoietic commitment at the hemangioblast stage of development in vitro.

Authors:  Georges Lacaud; Lia Gore; Marion Kennedy; Valerie Kouskoff; Paul Kingsley; Christopher Hogan; Leif Carlsson; Nancy Speck; James Palis; Gordon Keller
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

9.  AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis.

Authors:  T Okuda; J van Deursen; S W Hiebert; G Grosveld; J R Downing
Journal:  Cell       Date:  1996-01-26       Impact factor: 41.582

Review 10.  Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia.

Authors:  Motomi Osato
Journal:  Oncogene       Date:  2004-05-24       Impact factor: 9.867

View more
  3 in total

1.  The Runx transcriptional co-activator, CBFbeta, is essential for invasion of breast cancer cells.

Authors:  Daniel Mendoza-Villanueva; Wensheng Deng; Cesar Lopez-Camacho; Paul Shore
Journal:  Mol Cancer       Date:  2010-06-30       Impact factor: 27.401

2.  Is Runx a linchpin for developmental signaling in metazoans?

Authors:  James A Coffman
Journal:  J Cell Biochem       Date:  2009-05-15       Impact factor: 4.429

3.  Regulation of RUNX1 dosage is crucial for efficient blood formation from hemogenic endothelium.

Authors:  Michael Lie-A-Ling; Elli Marinopoulou; Andrew J Lilly; Mairi Challinor; Rahima Patel; Christophe Lancrin; Valerie Kouskoff; Georges Lacaud
Journal:  Development       Date:  2018-03-12       Impact factor: 6.868

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.